IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3626 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (153 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed1338    
    Printed52    
    Emailed0    
    PDF Downloaded107    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2010  |  Volume : 42  |  Issue : 1  |  Page : 57-58
 

Authors' reply


1 Department of Pharmacology, Government Medical College, Nagpur - 440 003, India
2 Department of Preventive and Social Medicine, Government Medical College, Nagpur - 440 003, India
3 Department of Skin and Venereal Diseases, Government Medical College, Nagpur - 440 003, India
4 Department of Rasa Shastra, Government Ayurvedic College, Nagpur - 440 009, India

Date of Web Publication12-Apr-2010

Correspondence Address:
V R Thawani
14-A, Jeevan Jyoti, Clarke Town, Nagpur - 440 004
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 20606843

Rights and PermissionsRights and Permissions



How to cite this article:
Kalikar M V, Thawani V R, Varadpande U K, Sontakke S D, Singh R P, Khiyani R K. Authors' reply. Indian J Pharmacol 2010;42:57-8

How to cite this URL:
Kalikar M V, Thawani V R, Varadpande U K, Sontakke S D, Singh R P, Khiyani R K. Authors' reply. Indian J Pharmacol [serial online] 2010 [cited 2020 Feb 25];42:57-8. Available from: http://www.ijp-online.com/text.asp?2010/42/1/57/62413


Sir,

We would like to thank Dr. Akhtar for his comments[1] on our paper.[2]

We agree that the baseline CD4 count of some participants (as factually reported by us) in TCE and placebo group was <200 / ul. This study was done in 2005-06 when free ART for HIV patients was not available anywhere in our city. Those patients coming to our hospital, who were not able to afford the ART from market and who volunteered to participate were included in this trial. Thus, even otherwise, the participants were just receiving symptomatic treatment for their opportunistic infection only. Had the ART treatment been available in our hospital at that time, we would have certainly put them on HAART and used TCE as add-on therapy.

Fall in Hb% cannot be attributed to TCE as it occurred in placebo group also at the end of six months and was comparable in both groups with no statistically significant difference

[Table 4].

Kruskal Wallis test was used by us in consultation with qualified statistician (see our acknowledgement) and the explanation offered for using this test was that if one wants to compare the mean of two groups and one is not sure about the distribution or sample size is small, a non parametric test like Kruskal Wallis test is used.

 
  References Top

1.Akhtar S. Use of Tinospora cordifolia in HIV infection. Indian J Pharmacol 2010;42:57.  Back to cited text no. 1    Medknow Journal  
2.Kalikar MV, Thawani VR, Varadpande UK, Sontakke SD, Singh RP, Khiyani RK. Immunomodulatory effect of Tinospora cordifolia extract in human immuno-deficiency virus positive patients. Indian J Pharmacol 2008;20:107-10.  Back to cited text no. 2      




 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow